DK1501505T3 - Anvendelse af (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-1,2,4 -triazol til behandling af autoimmune sygdomme - Google Patents

Anvendelse af (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-1,2,4 -triazol til behandling af autoimmune sygdomme

Info

Publication number
DK1501505T3
DK1501505T3 DK03720879T DK03720879T DK1501505T3 DK 1501505 T3 DK1501505 T3 DK 1501505T3 DK 03720879 T DK03720879 T DK 03720879T DK 03720879 T DK03720879 T DK 03720879T DK 1501505 T3 DK1501505 T3 DK 1501505T3
Authority
DK
Denmark
Prior art keywords
ethylphenyl
subject
triazole
methoxyphenyl
treatment
Prior art date
Application number
DK03720879T
Other languages
Danish (da)
English (en)
Inventor
L Battistini
G Borsellino
Santis R De
P Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1501505T3 publication Critical patent/DK1501505T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03720879T 2002-05-03 2003-04-15 Anvendelse af (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-1,2,4 -triazol til behandling af autoimmune sygdomme DK1501505T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
DK1501505T3 true DK1501505T3 (da) 2006-05-22

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03720879T DK1501505T3 (da) 2002-05-03 2003-04-15 Anvendelse af (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-1,2,4 -triazol til behandling af autoimmune sygdomme

Country Status (15)

Country Link
US (2) US6797722B2 (https=)
EP (1) EP1501505B1 (https=)
JP (1) JP2005529904A (https=)
KR (1) KR20040111491A (https=)
AT (1) ATE315935T1 (https=)
AU (1) AU2003224453A1 (https=)
CA (1) CA2483904A1 (https=)
DE (1) DE60303296T2 (https=)
DK (1) DK1501505T3 (https=)
ES (1) ES2257666T3 (https=)
MX (1) MXPA04010785A (https=)
PL (1) PL374252A1 (https=)
PT (1) PT1501505E (https=)
TW (1) TWI284532B (https=)
WO (1) WO2003092681A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (en) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE60303296T2 (de) 2006-08-17
PL374252A1 (en) 2005-10-03
EP1501505B1 (en) 2006-01-18
EP1501505A1 (en) 2005-02-02
JP2005529904A (ja) 2005-10-06
CA2483904A1 (en) 2003-11-13
ES2257666T3 (es) 2006-08-01
PT1501505E (pt) 2006-05-31
US20050026980A1 (en) 2005-02-03
MXPA04010785A (es) 2005-03-07
US6797722B2 (en) 2004-09-28
AU2003224453A1 (en) 2003-11-17
ATE315935T1 (de) 2006-02-15
TW200418464A (en) 2004-10-01
DE60303296D1 (de) 2006-04-06
WO2003092681A1 (en) 2003-11-13
KR20040111491A (ko) 2004-12-31
TWI284532B (en) 2007-08-01
US20030207931A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
EA199800119A1 (ru) Ингибиторы адгезии клеток
WO2004016597A3 (en) Protein kinase inhibitors and uses thereof
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
WO2003009773A3 (en) Removable stent and method of using the same
PL372316A1 (en) Glutaminyl based dpiv inhibitors
DE69939165D1 (de) N,n-disubstituierte amide welche die bindung von integrinen an ihre rezeptoren hemmen
EA200500856A1 (ru) Новые химические соединения
EA199700135A1 (ru) Ингибиторы клеточной адгезии
ATE263772T1 (de) Bizyklische pyrrolyl-amide als glukogen- phosphorylase-hemmer
DK0810889T3 (da) Implantat
ATE363290T1 (de) Cd40 antagonist zur behandlung von psoriasis
ATE113793T1 (de) Verfahren zur fungiziden blattbehandlung mit einem triazol und fungizide zusammensetzung zur durchführung dieses verfahrens.
AU8330898A (en) Substituted heterocycles and their use in medicaments
EE200100123A (et) CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DK1501505T3 (da) Anvendelse af (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-1,2,4 -triazol til behandling af autoimmune sygdomme
DK0804465T3 (da) Nye elastaseinhibitorer
ATE445235T1 (de) Verfahren zur herstellung von zinkpulver- agglomeraten und diese enthaltenden artikel
ATE352295T1 (de) Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
BRPI0415355A (pt) triarilimidazóis
ITPR970039A0 (it) Lega per rivestimenti o riporti resistenti alla corrosione.
WO2004099251A3 (en) Compositions and methods for treatment of cryptococcosis